Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas

Histopathology

Volumn 53, Issue 5, 2008, Pages 567-577

  Ettl, T ^a   Schwarz, S ^b   Kleinsasser, N ^c   Hartmann, A ^b   Reichert, T E ^a   Driemel, O ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

C KIT; EGFR; Ki67; Prognostic factors; Salivary gland cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SALIVARY GLAND NEOPLASMS; SURVIVAL ANALYSIS;

EID: 54949099258     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03159.x     Document Type: Article

References (44)

1. Cheuk W, Chan JK. Advances in salivary gland pathology. Histopathology 2007 51 1 20.
2. Patel RS, Rose B, Bawdon H et al. Cyclin D1 and p16 expression in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid gland. Histopathology 2007 51 691 696.
3. Meer S, Altini M. CK7+/CK20- immunoexpression profile is typical of salivary gland neoplasia. Histopathology 2007 51 26 32.
4. Patel RS, Hughes CW, Fredericks S et al. Cyclin A expression and its diagnostic value in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid gland. Histopathology 2007 51 21 25.
5. Therkildsen MH, Christensen M, Andersen LJ, Schiodt T, Hansen HS. Salivary gland carcinomas - prognostic factors. Acta Oncol. 1998 37 701 713.
6. Renehan AG, Gleave EN, Slevin NJ, McGurk M. Clinico-pathological and treatment-related factors influencing survival in parotid cancer. Br. J. Cancer 1999 80 1296 1300.
7. Bhattacharyya N, Fried MP. Determinants of survival in parotid gland carcinoma: a population-based study. Am. J. Otolaryngol. 2005 26 39 44.
8. Skalova A, Lehtonen H, von Boguslawsky K, Leivo I. Prognostic significance of cell proliferation in mucoepidermoid carcinomas of the salivary gland: clinicopathological study using MIB 1 antibody in paraffin sections. Hum. Pathol. 1994 25 929 935.
9. Luukkaa H, Klemi P, Leivo I, Vahlberg T, Grenman R. Prognostic significance of Ki-67 and p53 as tumor markers in salivary gland malignancies in Finland: an evaluation of 212 cases. Acta Oncol. 2006 45 669 675.
10. Okabe M, Inagaki H, Murase T, Inoue M, Nagai N, Eimoto T. Prognostic significance of p27 and Ki-67 expression in mucoepidermoid carcinoma of the intraoral minor salivary gland. Mod. Pathol. 2001 14 1008 1014.
11. Normanno N, De Luca A, Bianco C et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006 366 2 16.
12. Press MF, Pike MC, Hung G et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 1994 54 5675 5682.
13. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 2005 103 2526 2533.
14. Sorensen KB, Godballe C, de Stricker K, Krogdahl A. Parotid carcinoma: expression of kit protein and epidermal growth factor receptor. J. Oral Pathol. Med. 2006 35 286 291.
15. Glisson BS, Blumenschein G, Francisco M, Erasmus J, Zinner R, Kies M. Phase II trial of gefitinib in patients with incurable salivary gland carcinomas (RMSGCs): a monoinstitutional phase II study. Proc. Am. Soc. Clin. Oncol. 2005 23 508s abs 5532).
16. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998 279 577 580.
17. DiPaola RS, Kuczynski WI, Onodera K et al. Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene Ther. 1997 4 176 182.
18. Jeng YM, Lin CY, Hsu HC. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett. 2000 154 107 111.
19. Freier K, Flechtenmacher C, Walch A et al. Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland. Oral Oncol. 2005 41 934 939.
20. Mino M, Pilch BZ, Faquin WC. Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. Mod. Pathol. 2003 16 1224 1231.
21. Hotte SJ, Winquist EW, Lamont E et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J. Clin. Oncol. 2005 23 585 590.
22. Faivre S, Raymond E, Casiraghi O, Temam S, Berthaud P. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J. Clin. Oncol. 2005 23 6271 6273 author reply 6273 6274.
23. Sobin LH, Wittekind C eds. TNM classification of malignant tumours, 6th edn. New York : Wiley-Liss, Inc., 2002.
24. Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and genetics of head and neck tumours. World Health Organization classification of tumours. Lyon : IARC Press, 2005.
25. Milanes-Yearsley M, Hammond ME, Pajak TF et al. Tissue micro-array: a cost and time-effective method for correlative studies by regional and national cancer study groups. Mod. Pathol. 2002 15 1366 1373.
26. Vered M, Braunstein E, Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 2002 24 632 636.
27. Armstrong JG, Harrison LB, Thaler HT et al. The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer 1992 69 615 619.
28. Rodriguez-Cuevas S, Labastida S, Baena L, Gallegos F. Risk of nodal metastases from malignant salivary gland tumors related to tumor size and grade of malignancy. Eur. Arch. Otorhinolaryngol. 1995 252 139 142.
29. Felix A, El-Naggar AK, Press MF et al. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum. Pathol. 1996 27 561 566.
30. Wahlberg P, Anderson H, Biorklund A, Moller T, Perfekt R. Carcinoma of the parotid and submandibular glands - a study of survival in 2465 patients. Oral Oncol. 2002 38 706 713.
31. Terhaard CH, Lubsen H, Van der Tweel I et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 2004 26 681 692 discussion 692 683.
32. Skalova A, Leivo I, Von Boguslawsky K, Saksela E. Cell proliferation correlates with prognosis in acinic cell carcinomas of salivary gland origin. Immunohistochemical study of 30 cases using the MIB 1 antibody in formalin-fixed paraffin sections. J. Pathol. 1994 173 13 21.
33. Hellquist HB, Sundelin K, Di Bacco A, Tytor M, Manzotti M, Viale G. Tumour growth fraction and apoptosis in salivary gland acinic cell carcinomas. Prognostic implications of Ki-67 and bcl-2 expression and of in situ end labelling (TUNEL). J. Pathol. 1997 181 323 329.
34. Khan AJ, DiGiovanna MP, Ross DA et al. Adenoid cystic carcinoma: a retrospective clinical review. Int. J. Cancer 2001 96 149 158.
35. Lewis JE, Olsen KD, Sebo TJ. Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. Hum. Pathol. 2001 32 596 604.
36. Muller S, Vigneswaran N, Gansler T, Gramlich T, DeRose PB, Cohen C. c-erbB-2 oncoprotein expression and amplification in pleomorphic adenoma and carcinoma ex pleomorphic adenoma: relationship to prognosis. Mod. Pathol. 1994 7 628 632.
37. Glisson B, Colevas AD, Haddad R et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin. Cancer Res. 2004 10 944 946.
38. Holst VA, Marshall CE, Moskaluk CA, Frierson HF Jr. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod. Pathol. 1999 12 956 960.
39. Penner CR, Folpe AL, Budnick SD. C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod. Pathol. 2002 15 687 691.
40. Tsutsui S, Yasuda K, Suzuki K et al. A loss of c-kit expression is associated with an advanced stage and poor prognosis in breast cancer. Br. J. Cancer 2006 94 1874 1878.
41. Rohr UP, Rehfeld N, Pflugfelder L et al. Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer. Int. J. Cancer 2004 111 259 263.
42. Hong SM, Hwang I, Song DE, Choi J, Yu E. Clinical and prognostic significances of nuclear and cytoplasmic KIT expressions in extrahepatic bile duct carcinomas. Mod. Pathol. 2007 20 562 569.
43. Gibbons MD, Manne U, Carroll WR, Peters GE, Weiss HL, Grizzle WE. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope 2001 111 1373 1378.
44. Katopodi E, Patsouris E, Papanikolaou V, Karameris A, Douzinas E, Papanicolaou S. Immunohistochemical detection of epidermal growth factor and its receptor in salivary gland carcinomas. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2003 95 266 268.